Antimicrobial compositions containing cationic active ingredients

Abstract

The antimicrobial composition of the present invention comprises a cationic active ingredient, a foam boosting surfactant, a foam boosting copolymer, a foam stabilizer, and a chelating agent. The present antimicrobial compositions are free of the antimicrobial agent triclosan (i.e., 2,4,4′-trichloro-2′hydroxy-diphenylether), have rapid cidal activity, provide stable copious foam and exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.

What is claimed: 
     
         1 . An antimicrobial dermal concentrate comprising:
 (a) a cationic active ingredients;   (b) a foam boosting surfactant;   (c) a foam boosting copolymer   (d) a foam stabilizing, linear or branched C 5-12  diol with the structure   
       
         
           
           
               
               
           
         
          Wherein R 1 =H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , C(CH 3 ) 3 , CH(CH 3 ) 2  or combinations thereof and R 2  is a branched or linear C 1 -C 9  alkyl chain 
         (e) an aminocarboxylate chelating agent capable of forming a calcium-chelating agent complex with a stability constant (expressed logarithmically) of 5.5 or greater 
         (f) water, wherein said cleanser is substantially free of anionic surfactants, triclosan, and C 1-4  alcohols. 
       
     
     
         2 . The antimicrobial dermal concentrate of  claim 1 , wherein the cleanser comprises about 0.1 wt. % to about 10 wt. % of at least one cationic active ingredients. 
     
     
         3 . The antimicrobial dermal concentrate of  claim 1 , wherein the cationic active ingredient is selected from the group comprising of: a salt of a biguanide, a substituted biguanide derivative, an organic salt of a quaternary ammonium containing compound or an inorganic salt of a quaternary ammonium containing compound, chlorohexidene gluconate (CHG), and an organic salt of chlorohexidene gluconate (CHG). 
     
     
         4 . The antimicrobial dermal concentrate of  claim 1 , wherein the antimicrobial dermal concentrate comprises about 0.05 wt. % to about 12 wt. % foam boosting surfactants. 
     
     
         5 . The antimicrobial dermal concentrate of  claim 1 , wherein the foam boosting surfactant comprises a quaternized alkyl polyglucoside, a polyquaternized alkyl polyglucoside, an alkyl amine oxide, alkyl ether amine oxide, and polyethoxylated glycerol esters, or a combination thereof. 
     
     
         6 . The antimicrobial dermal concentrate of  claim 1 , wherein the foam boosting surfactant comprises a alkyl amine oxide or an alkyl ether amine oxide. 
     
     
         7 . The antimicrobial dermal concentrate of  claim 1 , wherein the foam boosting polymer is a dimethyldiallylammonium chloride-acrylamide copolymer with the following structure. 
     
     
         8 . The polymer of  claim 7  wherein dimethyldiallylammonium chloride-acrylamide copolymer has a molecular weight from about 500,000 to about 5,000,000 g/mol. 
     
     
         9 . The antimicrobial concentrate of  claim 1  wherein said a foam stabilizer is a linear or branched C 5-12  diol with the structure 
       
         
           
           
               
               
           
         
       
       wherein R=H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , C(CH 3 ) 3 , CH(CH 3 ) 2  or combinations thereof and R 2  is a branched or linear C 1 -C 9  alkyl chain. 
     
     
         10 . The antimicrobial concentrate of  claim 1  wherein said a foam stabilizer is hexylene glycol. 
     
     
         11 . The antimicrobial dermal concentrate of  claim 1  wherein said chelating agent is ethylenediaminetetraacetic acid (EDTA); diethylenetriaminepentaacetic acid (DTPA); methylglycine diacetic acid (MGDA), glutamic acid-N,N-diacetic acid (GLDA) aspartic acid-N,N-diacetic acid (ASDA) and alkali metal and/or ammonium salts thereof. 
     
     
         12 . The antimicrobial dermal concentrate of  claim 1  wherein the concentrate is diluted prior to or at the point of use to form a use solution wherein the ratio of concentrate to water is from about 1:1 to about 1:10. 
     
     
         13 . A method of reducing bacterial, microbial, fungicidal or viral population on a dermal tissue of a mammal comprising the step of:
 contacting the dermal tissue of a mammal with the dermal concentrate of  claim 1  for a sufficient time to provide substantial bacterial, microbial, fungicidal or viral reduction.   
     
     
         14 . The method of  claim 13  wherein the sufficient contact time is approximately about 1 to about 60 seconds. 
     
     
         15 . The method of  claim 13  wherein the dermal concentrate is rinsed off of the dermal tissue after contact or remains on the dermal tissue after contact. 
     
     
         16 . The method of  claim 13  wherein the dermal concentrate is diluted with water forming a use solution with a concentrate to water ratio from about 1:1 to about 1:10 
     
     
         17 . A antimicrobial use solution comprising:
 (a) a cationic active ingredient;   (b) a foam boosting surfactant;   (c) a foam boosting copolymer   (d) a foam stabilizing, linear or branched C 5-12  diol with the structure   
       
         
           
           
               
               
           
         
         wherein R 1 =H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , C(CH 3 ) 3 , CH(CH 3 ) 2  or combinations thereof and R 2  is a branched or linear C 1 -C 9  alkyl chain; 
         (e) an aminocarboxylate chelating agent capable of forming a calcium-chelating agent complex with a stability constant (expressed logarithmically) of 5.5 or greater 
         (f) water, wherein said cleanser is substantially free of anionic surfactants and substantially free of triclosan. 
       
     
     
         18 . The antimicrobial use solution of  claim 17 , wherein the cleanser comprises from about 100 ppm to about 50,000 ppm of at least one cationic ingredient selected from the group consisting of: a salt of a biguanide, a substituted biguanide derivative, an organic salt of a quaternary ammonium containing compound or an inorganic salt of a quaternary ammonium containing compound, chlorohexidene gluconate (CHG) and an organic salt of chlorhexidene gluconate (CHG). 
     
     
         19 . The antimicrobial composition of  claim 17 , wherein the said foam boosting surfactant comprises a quaternized alkylpolyglucoside, a quaternary alkyl polyglucoside, and alkyl amine oxide, alkyl ether amine oxide and polyethoxylated glycerol esters, or combinations thereof. 
     
     
         20 . The antimicrobial composition of  claim 17  wherein the composition comprises from about 50 ppm to about 50,000 ppm of foam boosting surfactant. 
     
     
         21 . The antimicrobial composition of  claim 17  wherein said foam boosting polymer is a dimethyldiallylammonium chloride-acrylamide copolymer. 
     
     
         22 . The polymer of  claim 17  wherein said dimethyldiallylammonium chloride-acrylamide copolymer has a molecular weight from about 500,000 to about 5,000,000 g/mol. 
     
     
         23 . The antimicrobial concentrate of  claim 17  wherein said a foam stabilizer is a linear or branched C 5-12  diol with the structure 
       
         
           
           
               
               
           
         
       
       wherein R=H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , C(CH 3 ) 3 , CH(CH 3 ) 2  or combinations thereof and R 2  is a branched or linear C 1 -C 9  alkyl chain. 
     
     
         24 . The antimicrobial composition of  claim 17  wherein the foam stabilizer is hexylene glycol. 
     
     
         25 . The antimicrobial composition of  claim 19  wherein the chelating agent is ethylenediamine tetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), methylglycine diacetic acid (MGDA), glutamic acid-N,N-diacetic acid (GLDA), aspartic acid-N,N-diacetic acid (ASDA) and alkali metal and/or ammonium salts thereof. 
     
     
         26 . The antimicrobial composition of  claim 25  wherein the chelating agent is present from about 10 ppm to about 20,000 ppm. 
     
     
         27 . A method of reducing bacterial, microbial, fungicidal or viral population on a dermal tissue of a mammal comprising the step of:
 contacting the dermal tissue of a mammal with the composition of  claim 16  for a sufficient time to provide substantial bacterial, microbial, fungicidal or viral reduction.   
     
     
         28 . The method of  claim 17  wherein the sufficient contact time is approximately about 1 to about 60 seconds. 
     
     
         29 . The method of  claim 17  wherein the dermal concentrate is rinsed off of the dermal tissue after contact or remains on the dermal tissue after contact.